Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors

5 Oct 2020

Abstract excerpt

Understanding differences in DNA double-strand break (DSB) repair between tumor and normal tissues would provide a rationale for developing DNA repair-targeted cancer therapy. Here, using knock-in mouse models for measuring the efficiency of two DSB repair pathways, homologous recombination (HR) and nonhomologous end-joining (NHEJ), we demonstrated that both pathways are up-regulated in hepatocellular carcinoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy
Share to Radiation Therapy and Dosimetry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33020270
DOI: 10.1073/pnas.2002917117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitorsPMID 33020270Read ↗

Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation.Semantic proximity Read ↗

TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinomaSemantic proximity Read ↗

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic DrugsSemantic proximity Read ↗

Targeting NAT10 attenuates homologous recombination via destabilizing DNA:RNA hybrids and overcomes PARP inhibitor resistance in cancersSemantic proximity Read ↗

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibitionSemantic proximity Read ↗

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cellsSemantic proximity Read ↗

PLK1 overexpression suppresses homologous recombination and confers cellular sensitivity to PARP inhibitionSemantic proximity Read ↗

Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathwaySemantic proximity Read ↗

Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient‐Derived Xenograft ModelsSemantic proximity Read ↗

Research advances in immunotherapy combined with DNA damage response inhibitors for liver cancer therapySemantic proximity Read ↗

LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination‐mediated DNA double strand break repairSemantic proximity Read ↗

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.